[go: up one dir, main page]

PE20050189A1 - Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local - Google Patents

Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local

Info

Publication number
PE20050189A1
PE20050189A1 PE2004000145A PE2004000145A PE20050189A1 PE 20050189 A1 PE20050189 A1 PE 20050189A1 PE 2004000145 A PE2004000145 A PE 2004000145A PE 2004000145 A PE2004000145 A PE 2004000145A PE 20050189 A1 PE20050189 A1 PE 20050189A1
Authority
PE
Peru
Prior art keywords
local administration
quinoloncarboxyl
acid derivatives
compositions including
refers
Prior art date
Application number
PE2004000145A
Other languages
English (en)
Inventor
Rainer Endermann
Harald Labischinski
Uwe Petersen
Ben Newton
Christoph Ladel
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32851853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10305319A external-priority patent/DE10305319A1/de
Priority claimed from DE10305318A external-priority patent/DE10305318A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20050189A1 publication Critical patent/PE20050189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A COMPOSICIONES QUE COMPRENDEN DERIVADOS DE ACIDO QUINOLONCARBOXILICO (CIPROFLOXACINO, ENROFLOXACINO) DE ADMINISTRACION LOCAL, PRESENTADAS EN LA FORMA DE BETAINA SOLIDA Y/O COMO SAL DE BETAINA SOLIDA ESCASAMENTE SOLUBLE , PREFERENTEMENTE COMO EMBONATOS (TAMBIEN CONOCIDOS COMO PAMOATOS). EL USO DE ESTOS COMPUESTOS PARA LA FABRICACION DE MEDICAMENTOS DE ADMINISTRACION LOCAL PARA EL TRATAMIENTO ENFERMEDADES BACTERIANAS DE LOS ORGANOS RESPIRATORIOS EN HOMBRES Y ANIMALES. TAMBIEN SE REFIERA A DISPOSITIVOS QUE SON APROPIADOS PARA LA ADMINISTACION INHALATORIA DEL PRINCIPIO ACTIVO SOLIDO Y CONTIENE PREPARADOS CON AL MENOS UNO DE LOS COMPUESTOS DEFINIDOS ANTERIORMENTE
PE2004000145A 2003-02-10 2004-02-09 Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local PE20050189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305319A DE10305319A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten
DE10305318A DE10305318A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten

Publications (1)

Publication Number Publication Date
PE20050189A1 true PE20050189A1 (es) 2005-05-22

Family

ID=32851853

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000145A PE20050189A1 (es) 2003-02-10 2004-02-09 Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local

Country Status (27)

Country Link
US (2) US8034817B2 (es)
EP (1) EP1594500B1 (es)
JP (2) JP4828405B2 (es)
KR (1) KR101173696B1 (es)
AR (1) AR043117A1 (es)
AT (1) ATE482706T1 (es)
AU (1) AU2004210399B2 (es)
BR (1) BRPI0407368A (es)
CA (1) CA2515262C (es)
CY (1) CY1110998T1 (es)
DE (1) DE502004011696D1 (es)
DK (1) DK1594500T3 (es)
EC (1) ECSP055959A (es)
HR (1) HRP20050786B1 (es)
IL (1) IL170027A (es)
MA (1) MA27632A1 (es)
MX (1) MXPA05008407A (es)
MY (1) MY144714A (es)
NO (1) NO331524B1 (es)
NZ (1) NZ541681A (es)
PE (1) PE20050189A1 (es)
PT (1) PT1594500E (es)
RU (1) RU2373937C9 (es)
SI (1) SI1594500T1 (es)
TW (1) TWI347843B (es)
UY (1) UY28179A1 (es)
WO (1) WO2004069253A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
ATE482706T1 (de) * 2003-02-10 2010-10-15 Bayer Schering Pharma Ag Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
WO2006033713A2 (en) * 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
US8846607B2 (en) 2004-10-29 2014-09-30 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
KR101621986B1 (ko) * 2008-05-15 2016-05-17 노파르티스 아게 플루오로퀴놀론의 폐 전달
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
US8168597B2 (en) 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
EP3569235A1 (en) 2009-09-04 2019-11-20 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2018074880A2 (ko) * 2016-10-20 2018-04-26 한국화학연구원 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3033157A1 (de) 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3525335A1 (de) * 1985-07-16 1987-01-22 Bayer Ag Embonate von chinoloncarbonsaeuren und ihren derivaten
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
FR2655545B1 (fr) * 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
RU2063770C1 (ru) * 1992-05-22 1996-07-20 Николай Сергеевич Скрипников Способ лечения гнойно-воспалительных заболеваний легких
RU2070045C1 (ru) * 1993-01-15 1996-12-10 Вячеслав Михайлович Провоторов Способ лечения хронического гнойного эндобронхита
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
DE19812160C1 (de) * 1998-03-20 1999-07-08 Bayer Ag Formkörper aus wirkstoffhaltigen thermoplastischen Polyurethanen
AU5528299A (en) * 1998-09-15 2000-04-03 Naeja Pharmaceutical Inc. Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)
CN1188111C (zh) * 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
CA2483218C (en) * 2002-04-25 2012-07-10 Nektar Therapeutics Uk Ltd Particulate materials
ATE482706T1 (de) * 2003-02-10 2010-10-15 Bayer Schering Pharma Ag Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen

Also Published As

Publication number Publication date
US20120010215A1 (en) 2012-01-12
AU2004210399A1 (en) 2004-08-19
WO2004069253A1 (de) 2004-08-19
MY144714A (en) 2011-10-31
RU2005128132A (ru) 2006-02-10
CA2515262A1 (en) 2004-08-19
RU2373937C9 (ru) 2010-07-27
CA2515262C (en) 2013-09-03
JP4828405B2 (ja) 2011-11-30
RU2373937C2 (ru) 2009-11-27
NO331524B1 (no) 2012-01-23
DE502004011696D1 (de) 2010-11-11
MXPA05008407A (es) 2005-10-05
ECSP055959A (es) 2006-01-16
NO20054180L (no) 2005-09-08
US8034817B2 (en) 2011-10-11
KR101173696B1 (ko) 2012-08-13
JP2006517210A (ja) 2006-07-20
NZ541681A (en) 2009-02-28
BRPI0407368A (pt) 2006-02-14
CY1110998T1 (el) 2015-06-11
DK1594500T3 (da) 2011-01-24
KR20050098309A (ko) 2005-10-11
JP2011173929A (ja) 2011-09-08
TWI347843B (en) 2011-09-01
EP1594500A1 (de) 2005-11-16
MA27632A1 (fr) 2005-11-01
SI1594500T1 (sl) 2011-02-28
NO20054180D0 (no) 2005-09-08
HK1089380A1 (zh) 2006-12-01
HRP20050786A2 (en) 2006-10-31
AR043117A1 (es) 2005-07-20
HRP20050786B1 (hr) 2015-01-02
TW200503716A (en) 2005-02-01
ATE482706T1 (de) 2010-10-15
IL170027A (en) 2012-02-29
AU2004210399B2 (en) 2010-02-18
UY28179A1 (es) 2004-09-30
EP1594500B1 (de) 2010-09-29
PT1594500E (pt) 2010-12-17
US20040254194A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CO6270364A2 (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos de proliferacion celular
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112013013950A2 (pt) antagonista de lpa1 policíclico e usos dos mesmos
UY28271A1 (es) Compuestos químicos
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
UY28702A1 (es) Derivados de quinazolina
UY28366A1 (es) Compuestos químicos
ATE543492T1 (de) Behandlung von lungenkrebs
IL259512B2 (en) Combination for the effective treatment of metastatic cancer in patients
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
AR057319A1 (es) Composicion para la administracion topica y metodo para evitar o tratar infeccion o infestacion endoparasitica y ectoparasitica en un animal de sangre caliente
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas

Legal Events

Date Code Title Description
FC Refusal